African Americans with hypertensive kidney disease benefit from an ACE inhibitor

Mahboob Rahman, MD, MS
Assistant Professor of Medicine, Divisions of Hypertension and Nephrology, Case Western Reserve University, University Hospitals of Cleveland; Louis Stokes Cleveland VA Medical Center; investigator, African American Study of Kidney Disease and Hypertension

Address: Mahboob Rahman, MD, MS, Divisions of Hypertension and Nephrology, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland OH 44106; e-mail: mxr9@po.cwru.edu

The author has indicated that he has received honoraria for speaking engagements from the Solvay, Abbott, and Pfizer companies.

Mahboob Rahman, MD, MS
Assistant Professor of Medicine, Divisions of Hypertension and Nephrology, Case Western Reserve University, University Hospitals of Cleveland; Louis Stokes Cleveland VA Medical Center; investigator, African American Study of Kidney Disease and Hypertension

Address: Mahboob Rahman, MD, MS, Divisions of Hypertension and Nephrology, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland OH 44106; e-mail: mxr9@po.cwru.edu

The author has indicated that he has received honoraria for speaking engagements from the Solvay, Abbott, and Pfizer companies.

Mahboob Rahman, MD, MS
Assistant Professor of Medicine, Divisions of Hypertension and Nephrology, Case Western Reserve University, University Hospitals of Cleveland; Louis Stokes Cleveland VA Medical Center; investigator, African American Study of Kidney Disease and Hypertension

Address: Mahboob Rahman, MD, MS, Divisions of Hypertension and Nephrology, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland OH 44106; e-mail: mxr9@po.cwru.edu

The author has indicated that he has received honoraria for speaking engagements from the Solvay, Abbott, and Pfizer companies.